In an era when the industry is being pressed to do more with less, interest in AI solutions is intense.
About 70% of pharma executives surveyed by Define Ventures said they consider AI an immediate priority. AI systems are already being used to identify the most promising compounds to speed drug development, assist with medical writing, and find trial sites and patients. An analysis from McKinsey & Company found that companies adding AI and machine learning can increase enrollment by as much as 20%, accelerating trial timelines.
Now agentic AI, a type of system that marks a significant shift from traditional AI models, is poised to make an impact in clinical research.
Clinical research associates have long been advisors for research sites. But as clinical trials grow increasingly complex, many now feel more like harried data cops, chasing down missing entries.
“Their…